Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pediatric Drugs
Published in: Pediatric Drugs 6/2016

01-12-2016 | Original Research Article

Doxapram Dosing for Apnea of Prematurity Based on Postmenstrual Age and Gender: A Randomized Controlled Trial

Authors: E. Greze, M. Benard, I. Hamon, C. Casper, F. E. Haddad, M.-J. Boutroy, J.-M. Hascoët

Published in: Pediatric Drugs | Issue 6/2016

Login to get access

Abstract

Introduction

Doxapram is used as a third-line treatment for apnea unresponsive to caffeine and continuous positive airway pressure (CPAP) in preterm infants.

Objectives

The objectives of this study were to compare the effects of dosing adjusted for gender and postmenstrual age (PMA) (GrA) versus infants’ weight alone (GrW) on doxapram plasma levels, clinical efficacy, and side effects.

Methods

This was a randomized, double-blind study, including premature infants for whom optimized caffeine and CPAP therapy for apnea of prematurity had failed. Failure was defined as the persistence of more than one significant apnea per hour over an 8-h period. Plasma levels of doxapram and ketodoxapram were measured with high-performance liquid chromatography (HPLC) 48 h after the onset of treatment. Dosing aimed to maintain the combined doxapram and ketodoxapram plasma level in the therapeutic range of 1.5–4 mg/l. Infants were followed-up for 4 days after the onset of treatment.

Results

A total of 85 infants were included: 46 in GrW (27.7 ± 1.9 weeks’ gestational age [GA]), 39 in GrA (27.9 ± 1.4 weeks’ GA); available plasma levels showed that 25 of 40 in the GrW group and 27 of 37 in the GrA group had levels within the therapeutic range (p = 0.344). Of note, plasma level variance was significantly higher in GrW for doxapram + ketodoxapram (1.87 vs. 0.89; p = 0.028). Clinical efficacy was better in the GrA group, with a reduction from 32 to 3 of 38 (76 %) infants with significant apnea versus 30 to 5 of 45 (56 %) in the GrW group (p < 0.001). No adverse effects were observed during the study.

Conclusions

Taking gender and PMA into account for doxapram dosing did not significantly increase the number of infants with a plasma level in the therapeutic range. However, it improved plasma level stability and clinical efficacy without adverse effects.
ClinicalTrials.gov number: NCT00389909.
Literature
1.
2.
Peliowski A. A blinded, randomized, placebo-controlled trial to compare theophylline and doxapram for the treatment of apnea of prematurity. J Pediatr. 1990;116:648–53.CrossRefPubMed
3.
4.
Bairam A. Pharmacodynamic effects and pharmacokinetic profiles of keto-doxapram and doxapram in newborn lambs. Pediatr Res. 1990;28:142–6.PubMed
5.
Barbé F. Severe side effects and drug plasma concentrations in preterm infants treated with doxapram. Ther Drug Monit. 1999;21:547–52.CrossRefPubMed
6.
Ten Hove CH, Vliegenthart RJ, Te Pas AB, et al. Long-Term Neurodevelopmental outcome after Doxapram for Apnea of Prematurity. Neonatology. 2016;110:21–6.CrossRefPubMed
7.
Caturla L. Sex-and age-related differences in doxapram pharmacokinetics in neonates: a population analysis. Paediatr Perinat Drug Ther. 2004,6:53–54.
8.
Hascoet JM. Risks and benefits of therapies for apnoea in premature infants. Drug Saf. 2000;23:363–79.CrossRefPubMed
9.
Maillard C. QT interval lengthening in premature infants treated with doxapram. Clin Pharmacol Ther. 2001;70:540–5.CrossRefPubMed
10.
Hascoet JM. The safety and efficacy of nitric oxide therapy in premature infants. J Pediatr. 2005;146:318–23.CrossRefPubMed
11.
Ancel PY. Survival and morbidity of preterm children born at 22 through 34 weeks’ gestation in France in 2011: results of the EPIPAGE-2 cohort study. JAMA Pediatr. 2015;169:230–8.CrossRefPubMed
12.
Morley CJ. Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med. 2008;358:700–8.CrossRefPubMed
13.
Tremblay LN. Pathogenesis of ventilator-induced lung injury: trials and tribulations. Am J Physiol Lung Cell Mol Physiol. 2005;288:L596–8.CrossRefPubMed
14.
15.
Fanni D. Cytochrome P450 genetic polymorphism in neonatal drug metabolism: role and practical consequences towards a new drug culture in neonatology. Int J Immunopathol Pharmacol. 2014;27:5–13.PubMed
16.
Hamon I, Valdes V, Franck P, et al. Gender-dependent differences in glutathione (GSH) metabolism in very preterm infants. Arch Pediatr. 2011;18:247–52.CrossRefPubMed
17.
Ogawa Y, Irikura M, Kobaru Y, et al. Population pharmokinetics of doxapram in low-birth-weight Japanese infants with apneas. Eur J Pediatr. 2015;174:509–18.CrossRefPubMed
18.
Henderson-Smart DJ. Doxapram versus methylxanthine for apnea in preterm infants. Cochrane Database Syst Rev. 2000;(4):CD000075.
19.
Henderson-Smart DJ. Doxapram treatment for apnea in preterm infants. Cochrane Database Syst Rev. 2000;(2):CD000074 (Update in: Cochrane Database Syst Rev. 2001;(4):CD000074).
20.
Hayakawa F, Hakamada S, Kuno K, et al. Doxapram in the treatment of idiopathic apnea of prematurity: Desirable dosage and serum concentrations. J Pediatr. 1986;109:138–40.CrossRefPubMed
21.
22.
Barrington KJ, Finer NN, Torok-Both G, et al. Dose-response relationship of doxapram in the therapy for refractory idiopathic apnea of prematurity. Pediatrics. 1987;80:22–7.PubMed
23.
Bénard M. Determinants of doxapram utilization: a survey of practice in the French Neonatal and Intensive Care Units. Arch Pediatr. 2005;12:151–5.CrossRefPubMed
24.
Eyal F, Alpan G, Sagi E, et al. aminophylline versus doxapram in idiopathic apnea of prematurity: a double-blind controlled study. Pediatrics. 1985;75:709–13.PubMed
25.
Tay-Uyboco J. Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity. Biol Neonate. 1991;59:190–200.CrossRefPubMed
26.
Huon C, Rey E, Mussat P, et al. Low-dose doxapram for treatment of apnoea following early weaning in very low birthweight infants: a randomized, double-blind study. Acta Paediatr. 1998;87(11):1180–4.CrossRefPubMed
Metadata
Title
Doxapram Dosing for Apnea of Prematurity Based on Postmenstrual Age and Gender: A Randomized Controlled Trial
Authors
E. Greze
M. Benard
I. Hamon
C. Casper
F. E. Haddad
M.-J. Boutroy
J.-M. Hascoët
Publication date
01-12-2016
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 6/2016
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-016-0192-2

Other articles of this Issue 6/2016

Pediatric Drugs 6/2016 Go to the issue

Therapy in Practice

First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients

Original Research Article

Palivizumab Exposure and the Risk of Autoimmune Disease: A Cross-National Cohort Study

Systematic Review

Opioid-Sparing Effect of Ketamine in Children: A Meta-Analysis and Trial Sequential Analysis of Published Studies

Therapy in Practice

Management of Juvenile Idiopathic Arthritis: A Clinical Guide

Erratum

Erratum to: A Mechanism to Explain Ototoxicity in Neonates Exposed to Bumetanide: Lessons to Help Improve Future Product Development in Neonates

Acknowledgement to Referees

Acknowledgement to Referees